Zhejiang Doer Biologics Co., Ltd., a China-based clinical stage biopharmaceutical company, announced on Friday that it has completed the enrolment in the phase 1b/2a trial assessing DR10624 in obese patients with modest hypertriglyceridemia in New Zealand.

DR10624 is a first-in-class (FIC), long-acting tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon-like peptide-1 receptor (GLP-1R), and Glucagon receptor (GCGR).

The Phase 1b/2a study is a randomised, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DR10624 in adult obese subjects (BMI of 30 to 45 kg/m2) with modest hypertriglyceridemia (fasting triglyceride greater than or equal to 150mg/dL (1.7mmol/L), and